News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
445,615 Results
Type
Article (20056)
Company Profile (317)
Press Release (425235)
Multimedia
Podcasts (88)
Webinars (14)
Section
Business (134398)
Career Advice (626)
Deals (23941)
Drug Delivery (50)
Drug Development (59299)
Employer Resources (60)
FDA (9124)
Job Trends (8356)
News (224835)
Policy (16311)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (1290)
Accelerated approval (27)
Adcomms (18)
Allergies (104)
Alliances (32296)
ALS (142)
Alzheimer's disease (1187)
Antibody-drug conjugate (ADC) (276)
Approvals (9366)
Artificial intelligence (341)
Autoimmune disease (150)
Automation (16)
Bankruptcy (189)
Best Places to Work (6695)
BIOSECURE Act (8)
Biosimilars (141)
Biotechnology (247)
Bladder cancer (117)
Brain cancer (52)
Breast cancer (429)
Cancer (3723)
Cardiovascular disease (302)
Career advice (545)
Career pathing (12)
CAR-T (240)
CDC (13)
Celiac Disease (1)
Cell therapy (638)
Cervical cancer (19)
Clinical research (51369)
Collaboration (1398)
Company closure (2)
Compensation (853)
Complete response letters (51)
COVID-19 (1366)
CRISPR (96)
C-suite (766)
Cystic fibrosis (124)
Data (5056)
Denatured (20)
Depression (105)
Diabetes (297)
Diagnostics (3453)
Digital health (23)
Diversity (6)
Diversity, equity & inclusion (19)
Drug discovery (223)
Drug pricing (79)
Drug shortages (5)
Duchenne muscular dystrophy (234)
Earnings (57934)
Editorial (32)
Employer branding (10)
Employer resources (59)
Events (77288)
Executive appointments (834)
FDA (11363)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1192)
Gene editing (198)
Generative AI (27)
Gene therapy (553)
GLP-1 (634)
Government (1645)
Grass and pollen (3)
Guidances (266)
Healthcare (10492)
HIV (32)
Huntington's disease (46)
IgA nephropathy (82)
Immunology and inflammation (220)
Immuno-oncology (51)
Indications (93)
Infectious disease (1505)
Inflammatory bowel disease (172)
Inflation Reduction Act (11)
Influenza (58)
Intellectual property (195)
Interviews (76)
IPO (11994)
IRA (26)
Job creations (1933)
Job search strategy (489)
JPM (43)
Kidney cancer (13)
Labor market (34)
Layoffs (358)
Leadership (15)
Legal (3730)
Liver cancer (55)
Longevity (15)
Lung cancer (492)
Lymphoma (284)
Machine learning (30)
Management (17)
Manufacturing (496)
MASH (159)
Medical device (6412)
Medtech (6433)
Mergers & acquisitions (12802)
Metabolic disorders (878)
mRNA (123)
Multiple sclerosis (121)
NASH (19)
Neurodegenerative disease (270)
Neuropsychiatric disorders (77)
Neuroscience (2240)
Neurotech (1)
NextGen: Class of 2026 (3480)
Non-profit (1774)
Now hiring (36)
Obesity (409)
Opinion (171)
Ovarian cancer (140)
Pain (122)
Pancreatic cancer (192)
Parkinson's disease (261)
Partnered (17)
Patents (351)
Patient recruitment (405)
Peanut (51)
People (43273)
Pharmaceutical (48)
Pharmacy benefit managers (12)
Phase 1 (17344)
Phase 2 (23268)
Phase 3 (15919)
Pipeline (4617)
Policy (135)
Postmarket research (1365)
Preclinical (7239)
Press Release (68)
Prostate cancer (189)
Psychedelics (51)
Radiopharmaceuticals (274)
Rare diseases (768)
Real estate (3185)
Recruiting (22)
Regulatory (13981)
Reports (27)
Research institute (1338)
Resumes & cover letters (87)
Rett syndrome (30)
RNA editing (21)
RSV (22)
Schizophrenia (140)
Series A (215)
Series B (164)
Service/supplier (1)
Sickle cell disease (85)
Special edition (21)
Spinal muscular atrophy (128)
Sponsored (21)
Startups (2592)
State (1)
Stomach cancer (6)
Supply chain (44)
Tariffs (26)
The Weekly (67)
Vaccines (434)
Venture capital (73)
Weight loss (212)
Women's health (38)
Worklife (4)
Date
Last 7 days (506)
Last 30 days (1934)
Last 365 days (21999)
2026 (3970)
2025 (22420)
2024 (25821)
2023 (28960)
2022 (37081)
2021 (39019)
2020 (35058)
2019 (26240)
2018 (19892)
2017 (20633)
2016 (18652)
2015 (22850)
2014 (17707)
2013 (13883)
2012 (14723)
2011 (15238)
2010 (14749)
Location
Africa (353)
Alabama (75)
Alaska (3)
Arizona (144)
Arkansas (6)
Asia (25917)
Australia (4085)
California (8897)
Canada (2500)
China (862)
Colorado (323)
Connecticut (362)
Delaware (266)
Europe (56799)
Florida (1219)
Georgia (251)
Hawaii (2)
Idaho (34)
Illinois (547)
India (53)
Indiana (243)
Iowa (12)
Japan (355)
Kansas (97)
Kentucky (24)
Louisiana (16)
Maine (63)
Maryland (914)
Massachusetts (7013)
Michigan (209)
Minnesota (391)
Mississippi (4)
Missouri (73)
Montana (21)
Nebraska (18)
Nevada (72)
New Hampshire (37)
New Jersey (2263)
New Mexico (15)
New York (2206)
North Carolina (1134)
North Dakota (8)
Northern California (4398)
Ohio (251)
Oklahoma (15)
Oregon (26)
Pennsylvania (1633)
Puerto Rico (10)
Rhode Island (37)
South America (489)
South Carolina (25)
Southern California (3500)
Tennessee (108)
Texas (1287)
United States (30527)
Utah (204)
Virginia (213)
Washington D.C. (51)
Washington State (721)
West Virginia (3)
Wisconsin (92)
Wyoming (1)
445,615 Results for "boehringer mannheim corporation therapeutics division bmct".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Boehringer Seeks To Rebalance Immunity With Sitryx Collab Potentially Worth $500M+
While Boehringer Ingelheim hasn’t yet revealed what diseases it will go after, Sitryx’s oral drug candidate could potentially be disease-modifying for a variety of autoimmune and inflammatory conditions.
February 26, 2026
·
1 min read
·
Tristan Manalac
Press Releases
Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics
February 26, 2026
·
3 min read
Inflammatory bowel disease
Boehringer Commits up to $1.26B in IBD Pact With China’s Simcere
The cornerstone of the deal is SIM0709, which Simcere designed to target both TL1A and IL-23, crucial players in facilitating inflammation. Boehringer Ingelheim will advance the asset for inflammatory bowel diseases.
January 27, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Numab Therapeutics Achieves Milestone in Second Collaboration Project with Boehringer Ingelheim
December 19, 2025
·
2 min read
Collaboration
Boehringer Ingelheim Bets up to Nearly $1B in ADC Play With AimedBio Deal
2025 has been a busy year for Boehringer Ingelheim, which has so far inked at least five hefty partnerships—including its latest one with South Korea’s AimedBio for an antibody-drug conjugate therapy for cancer.
October 15, 2025
·
2 min read
·
Tristan Manalac
MASH
Boehringer Ingelheim Axes MASH Pact With OSE After Disappointing Mid-Stage Data
OSE Immunotherapeutics has kicked off a strategic realignment initiative that involves deprioritizing the AbbVie-partnered OSE-230 and focusing its resources on the late-stage development of its ulcerative colitis candidate lusvertikimab.
March 3, 2026
·
2 min read
·
Tristan Manalac
Approvals
Boehringer Wins Speedy Lung Cancer Approval Under Commissioner’s Priority Program
Hernexeos is the second drug to secure an FDA approval under the agency’s priority voucher scheme, following in the footsteps of USAntibiotics’ Augmentin XR, which was granted the ticket in December 2025.
February 27, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Numab Therapeutics Achieves Milestone in Collaboration with Boehringer Ingelheim
September 26, 2025
·
2 min read
Press Releases
Boehringer Ingelheim announces appointment to Board of Managing Directors
December 1, 2025
·
2 min read
Press Releases
Boehringer Ingelheim Obtains Novel Preclinical Oncology Program from Accent Therapeutics
October 9, 2025
·
2 min read
1 of 44,562
Next
